168 related articles for article (PubMed ID: 22940405)
1. Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma.
Boyd KP; Vincent B; Andea A; Conry RM; Hughey LC
J Am Acad Dermatol; 2012 Dec; 67(6):1375-9. PubMed ID: 22940405
[TBL] [Abstract][Full Text] [Related]
2. A case of vemurafenib-induced keratosis pilaris-like eruption.
Wang CM; Fleming KF; Hsu S
Dermatol Online J; 2012 Apr; 18(4):7. PubMed ID: 22559022
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway.
Huang V; Hepper D; Anadkat M; Cornelius L
Arch Dermatol; 2012 May; 148(5):628-33. PubMed ID: 22431713
[TBL] [Abstract][Full Text] [Related]
4. Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption.
Braunstein I; Gangadhar TC; Elenitsas R; Chu EY
J Cutan Pathol; 2014 Jun; 41(6):539-43. PubMed ID: 24517243
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks.
Anforth R; Carlos G; Clements A; Kefford R; Fernandez-Peñas P
Br J Dermatol; 2015 Jan; 172(1):239-43. PubMed ID: 25040674
[TBL] [Abstract][Full Text] [Related]
8. Vemurafenib-induced eccrine squamous syringometaplasia.
Lescoat A; Droitcourt C; Stock N; Le Gall F; Dupuy A
Dermatology; 2013; 226(4):362-4. PubMed ID: 23860306
[TBL] [Abstract][Full Text] [Related]
9. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
10. Sarcoidosis in Patients Treated with Vemurafenib for Metastatic Melanoma: A Paradoxical Autoimmune Activation.
Lheure C; Kramkimel N; Franck N; Laurent-Roussel S; Carlotti A; Queant A; Goldwasser F; Avril MF; Dupin N
Dermatology; 2015; 231(4):378-84. PubMed ID: 26452227
[TBL] [Abstract][Full Text] [Related]
11. Multiple white cysts on face and trunk of a melanoma patient treated with vemurafenib.
Gebhardt C; Staub J; Schmieder A; Goerdt S; Utikal J
Acta Derm Venereol; 2015 Jan; 95(1):96-7. PubMed ID: 24710689
[No Abstract] [Full Text] [Related]
12. Vemurafenib and radiosensitization.
Boussemart L; Boivin C; Claveau J; Tao YG; Tomasic G; Routier E; Mateus C; Deutsch E; Robert C
JAMA Dermatol; 2013 Jul; 149(7):855-7. PubMed ID: 23699661
[TBL] [Abstract][Full Text] [Related]
13. Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.
Peters S; Bouchaab H; Zimmerman S; Bucher M; Gaide O; Letovanec I; Homicsko K; Michielin O
Melanoma Res; 2014 Oct; 24(5):496-500. PubMed ID: 25185693
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous side effects of vemurafenib: a case report and discussion.
Shea SM; Boyd K; Patterson J
Wien Med Wochenschr; 2013 Aug; 163(15-16):376-9. PubMed ID: 23824179
[TBL] [Abstract][Full Text] [Related]
15. Hidradenitis suppurativa, eruptive melanocytic nevi, and keratosis pilaris-like eruption in a patient treated with vemurafenib.
Ma L; Dominguez AR; Collins GR; Kia KF; Cockerell CJ
Arch Dermatol; 2012 Dec; 148(12):1428-9. PubMed ID: 23247496
[No Abstract] [Full Text] [Related]
16. Histopathological features of cutaneous drug reactions to vemurafenib: a report of two cases.
Dabner M; Harvey NT; Soma A; Wood BA
Pathology; 2012 Dec; 44(7):661-4. PubMed ID: 23172086
[No Abstract] [Full Text] [Related]
17. Cutaneous adverse events during vemurafenib therapy.
Chandrakumar SF; Yeung J
J Cutan Med Surg; 2014; 18(4):223-8. PubMed ID: 25008438
[TBL] [Abstract][Full Text] [Related]
18. Vemurafenib-induced granuloma annulare.
Lee SB; Weide B; Ugurel S; Mössner R; Enk A; Hassel JC
J Dtsch Dermatol Ges; 2016 Mar; 14(3):305-8. PubMed ID: 26972200
[No Abstract] [Full Text] [Related]
19. Targeting the adnexal epithelium: an unusual case of syringometaplasia in a patient on vemurafenib.
Yu J; Ravikumar S; Plaza JA; Troy JL; Schieke SM
Am J Dermatopathol; 2015 May; 37(5):e57-60. PubMed ID: 25839889
[TBL] [Abstract][Full Text] [Related]
20. Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas.
Regnier-Rosencher E; Lazareth H; Gressier L; Avril MF; Thervet E; Dupin N
Br J Dermatol; 2013 Oct; 169(4):934-8. PubMed ID: 23909652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
